Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

Data ReadoutpositiveEB613Positive

AI Analysis

Summary

Entera Bio announced that Phase 2 data for EB613 (oral PTH(1-34)) demonstrating anabolic effects in postmenopausal women with osteoporosis at high fracture risk has been selected for a plenary poster presentation at the ASBMR 2026 Annual Meeting.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Phase 2 data supporting EB613's anabolic effect selected for plenary poster presentation

Importance:6/10

Sentiment:

0.60

osteoporosisPhase 2 dataoral PTHpostmenopausal womenASBMR conferenceanabolic effect

Related Companies

$ENTX

Read the original article

Published by yahoo_finance on August 4, 2026 12:30 PM

Read Original